Increasing the number of targeted therapies and reducing the cost of genetic testing globally

Company logo

Firm brand

International lung most cancers genome testing market

Global lung cancer genome testing market

International lung most cancers genome testing market

Dublin, June 22, 2022 (GLOBE NEWSWIRE) – The “Lung Most cancers Genome Testing Market – International and Regional Evaluation: Product Focus, Expertise, Panel Kind, Pattern Kind and Finish Person – Evaluation and Forecasting, 2021-2031” Report added to ResearchAndMarkets.com Present.

The marketplace for genomic testing medicine for lung most cancers was valued at $1,262.0 million in 2020 and is anticipated to achieve $3,279.8 million by 2031, at a compound annual development charge of 8.97% over the forecast interval 2021-2031.

The expansion within the international lung most cancers genetic testing market is anticipated to be pushed by the elevated consciousness and adoption of the lung most cancers genetic testing market, the latest launch of a brand new lung most cancers genetic take a look at, and the growth of analysis into lung most cancers with a spotlight. On pharmacogenomics and improvement of concomitant diagnoses.

North America is anticipated to dominate the worldwide marketplace for genetic testing for lung most cancers, with the very best income of $713.5 million. That is because of the presence of a lot of analysis organizations and product and repair firms in the USA

Market life cycle stage

The worldwide lung most cancers genetic testing market remains to be within the strategy of being fashioned. A number of firms are growing investments in analysis and improvement to facilitate the event of genetic assessments for lung most cancers, which is anticipated to extend the adoption of genetic testing for lung most cancers.

The shift in well being care methods towards correct analysis and precision drugs will result in the adoption of genetic testing for lung most cancers, facilitating knowledgeable therapy selections and bettering well being care outcomes. The growing suggestions by worldwide oncology societies for the usage of genetic testing to diagnose lung most cancers presents vital alternatives within the international lung most cancers genetic testing market.

The presence of main suppliers of in vitro diagnostics (IVD) merchandise for lung most cancers genetic testing in areas reminiscent of North America and Europe has a major impression available on the market. For instance, Qiagen supplies Therascreen Assays for Strong Tumor, a real-time polymerase chain response (PCR) take a look at for detecting EGFR in non-small cell lung most cancers (NSCLC) sufferers. As well as, Roche supplies the Cobas EGFR mutation take a look at, a PCR-based take a look at, and FoundationOne CDx from Basis Medication Inc. , a subsequent era sequencing (NGS)-based assay for NSCLC.

LDTs suppliers present genomic lung most cancers assessments in areas reminiscent of North America and Europe, which have a major impression available on the market. LDT assessments are supplied by the US Quest Diagnostics and Laboratory Company (Labcorp), which goal completely different lung most cancers genes, for instance, EGFR, MET, ALK and ROS, primarily based on fluorescent in situ hybridization (FISH) and NGS. The presence of those firms has a optimistic impression on market development.

Influence of COVID-19

Utility in diagnostic laboratories, hospitals, and clinics dominates the worldwide lung most cancers genetic testing market. Throughout the onset of the COVID-19 pandemic, many nations skilled full or partial lockdown, and all elective surgical procedures and procedures in healthcare settings have ceased.

As lung most cancers genomic testing has been labeled below the elective process, the impression of the COVID-19 pandemic on lung most cancers genetic testing has been unfavourable. BIS Analysis evaluation concluded that the market witnessed a 3.24% lower within the annual development charge of the worldwide Lung Most cancers Genetic Testing Market.

Market segmentation

Product kind (merchandise, companies)

The worldwide lung most cancers genetic testing companies sector is anticipated to dominate. That is because of the ease of availability, accessibility and flexibility of lab-developed assessments, because of the decrease value when in comparison with the IVD product market.

Expertise (polymerase chain response (PCR), subsequent era sequencing (NGS), fluorescence in situ hybridization, others)

The worldwide marketplace for genomic testing for lung most cancers by polymerase chain response (PCR) is anticipated to dominate the worldwide market. That is because of the total cost-efficiency and excessive sensitivity of the PCR-based genetic take a look at for detecting disease-causing mutations in lung most cancers.

Specimen kind (tissue biopsy, liquid biopsy)

The worldwide lung most cancers genomic testing market is anticipated to be dominated by tissue biopsy pattern kind. This is because of customary healthcare practices of biopsy extraction of lung tissue to diagnose lung most cancers, which can be utilized in genetic testing for lung most cancers.

Plaque kind (polygenic plaque, monogenetic plaque)

The worldwide lung most cancers genomic testing market is anticipated to be dominated by polygenic panel kind. This is because of customary healthcare practices and healthcare professionals’ familiarity with lung tissue biopsy extraction for lung most cancers analysis, which can be utilized in genetic testing for lung most cancers.

Finish Person (Analysis Establishment, Hospitals/Clinics, Diagnostic Laboratories, Different Finish Customers)

The top consumer of the analysis group is anticipated to dominate the worldwide lung most cancers genetic testing market. That is because of the giant variety of medical analysis and tutorial establishments the place lung most cancers genetic testing is used to develop medicine, develop concomitant diagnoses, and enroll sufferers in medical trials.

Current Developments within the International Lung Most cancers Genome Testing Market

  • In December 2021, the FDA accepted a companion NGS-based diagnostic from Thermo Fisher Scientific for EGFR Exon20 mutant non-small cell lung most cancers tumor tissue for insertion, the Oncomine Dx Goal Take a look at, now accepted for 12 focused therapies from NSCLC Worldwide.

  • In September 2021, the FDA accepted a tissue-based NGS companion analysis from Thermo Fisher Scientific for Takeda-targeted remedy for NSCLC sufferers with EGFR Exon20 insertion mutations—the Oncomine Dx Goal Take a look at is now accepted as a CDx for 5 focused therapies for NSCLC in the USA

  • In September 2020, Laboratory Company of America Holdings entered right into a enterprise partnership with Decision Bioscience; The corporate has carried out a CtDx liquid lung biopsy take a look at.

  • In Could 2021, Qiagen launched the primary FDA-approved histopathological analysis to establish the KRAS G12C mutation in NSCLC tumors and broaden precision drugs choices in lung most cancers.

  • In January 2020, Qiagen constructed a worldwide collaboration with Amgen to develop an related analysis of non-small cell lung most cancers.

The most important gamers available in the market and competitors abstract

  • QIAGEN NV

  • Agilent Applied sciences, Inc.

  • Thermo Fisher Scientific, Inc.

  • Quest Diagnostics Included

  • American Laboratories Holding Firm

  • Centogen Nevada

  • BGI

  • CeGaT GmbH

  • Illumina, Inc.

  • F. Hoffmann-La Roche Ltd.

  • Abbott Laboratories

  • Genomics CD

  • NeoGenomics Laboratories

  • Admira Well being

  • Unko DNA

  • OPKO Well being, Inc.

  • Invitae Firm

  • Veracyte, Inc.

Primary matters lined:

1 markets

2 Market Overview
2.1 Introduction
2.2 International prevalence of lung most cancers
2.3 The significance of genomic testing in lung most cancers
2.4 Influence of COVID-19 on the Lung Most cancers Genome Testing Market
2.4.1 Disruption within the International Lung Most cancers Genome Testing Market: Earlier than and After COVID-19 Market Evaluation
2.4.2 COVID-19 impacts the worldwide lung most cancers genetic testing market provide chain
2.4.3 Scientific R&D and industrial operations halted
2.4.4 Navigating restoration from crises and trying to the long run

3 Business Evaluation
3.1 International Authorized Necessities and Rules
3.1.1 US Authorized Necessities and Frameworks
3.1.1.1 Group of medical care and medical companies facilities
3.1.2 Authorized frameworks and necessities in Europe
3.1.3 Authorized Necessities and Frameworks within the Asia Pacific Area
3.1.4 Latin America (Brazil and Mexico)
3.2 patent scene
3.2.1 Patent submitting development
3.2.2 Patent evaluation by nation
3.2.3 Patent Evaluation by Expertise

4 market dynamics
4.1 Overview
4.2 Influence Evaluation
4.3 Market Drivers
4.3.1 Excessive charge of lung most cancers mortality
4.3.2 Advances in Subsequent-Era Applied sciences for Genome Testing
4.3.3 Enhance the variety of focused therapies
4.3.4 Low value of genetic testing globally
4.4 Market Proscribing Elements
4.4.1 Unsure regulatory situation for genomic testing
4.4.2 Insufficient biopsy pattern
4.4.3 Unequal reimbursement situation for genomic testing
4.5 Market Alternatives
4.5.1 Enhancing international suggestions for genomic testing for lung most cancers
4.5.1.1 Suggestions of the American Society of Scientific Oncology (ASCO)
4.5.1.2 Suggestions of the European Society of Scientific Oncology (ESMO)
4.5.1.3 Pan-Asian Scientific Sensible Tips
4.5.2 Enhance funding in analysis and improvement
4.5.3 Rising economies

5 aggressive panorama
5.1 Key Methods and Developments
5.1.1 Synergistic actions
5.1.2 Regulatory approvals
5.1.3 Product launches and promotions
5.1.4 Mergers and Acquisitions
5.1.5 Enterprise Enlargement
5.1.6 Funding, Financing and Joint Ventures
5.1.7 Market share evaluation by the corporate
5.1.8 Development and inventory evaluation by firm

6 International Lung Most cancers Genome Testing Market, (by Product Kind), Million {Dollars}, 2020-2031
6.1 Overview
6.1.1 Merchandise
6.1.2 Providers

7 International Lung Most cancers Genetic Testing Market, (by know-how), Million {Dollars}, 2020-2031
7.1 Overview
7.2 Subsequent era sequencing
7.3 Polymerase chain response (PCR)
7.4 In situ hybridization (FISH) / In situ hybridization (ISH)
7.5 different

8 International Lung Most cancers Genome Testing Market, (by Panel Kind), Million {Dollars}, 2020-2031
8.1 Overview
8.2 One gene
8.3 polygenic panel

9 International Lung Most cancers Genetic Testing Market, (by pattern kind), Million {Dollars}, 2020-2031
9.1 Overview
9.2 Tissue biopsy
9.3 Liquid biopsy
9.3.1 CFDNA
9.3.2 ctDNA

10 International Lung Most cancers Genetic Testing Market, (by finish consumer), Million {Dollars}, 2020-2031
10.1 Overview
10.2 Analysis Group
10.3 Hospitals / Clinics
10.4 Diagnostic laboratories
10.5 Different customers

11 International Lung Most cancers Genetic Testing Market (by Area), Million {Dollars}, 2020-2031
11.1 Overview

12 Firm Profiles
12.1 Firm Overview
12.2 Function within the International Lung Most cancers Genome Testing Market
12.3 Primary rivals
12.4 Primary prospects
12.5 Finance
12.6 Firm Methods
12.7 SWOT Evaluation

For extra details about this report go to https://www.researchandmarkets.com/r/ngy4vz

Connected

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wooden, Senior Press Supervisor press@researchandmarkets.com For E.S.T Workplace Hours Name 1-917-300-0470 For U.S./CAN Toll Free Name 1-800-526-8630 For GMT Workplace Hours Name +353-1-416-8900